In recent transactions filed with the Securities and Exchange Commission, South Lake One LLC and South Cone Investments Limited Partnership disclosed significant sales of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) stock. The transactions, dated October 15, 2024, involved the sale of over 3.8 million shares, resulting in total proceeds of approximately $10 million.
The sales were executed in two separate transactions. The first transaction involved the sale of 3,305,622 shares at a weighted average price of $2.5521, bringing in around $8.4 million. The second transaction saw 523,738 shares sold at an average price of $3.2562, totaling approximately $1.7 million. These shares were indirectly held through South Lake One LLC, with South Cone Investments Limited Partnership owning a full interest in the entity.
Following these transactions, the reporting entities continue to hold a substantial number of shares in Rani Therapeutics, indicating ongoing investment in the company.
In other recent news, Rani Therapeutics has reported significant developments. The clinical-stage biotherapeutics company has announced new data from a preclinical study, suggesting that its RaniPill platform could effectively administer obesity treatments orally. The company also plans to initiate a Phase 1 clinical trial for RT-114, an oral GLP-1/GLP-2 dual agonist, in 2025.
In financial news, Rani Therapeutics has secured approximately $10 million through a registered direct offering and reported a Q2 net loss of $0.51 per share, consistent with expectations. Following this, H.C. Wainwright adjusted its 12-month price target for the company from $13 to $9, while maintaining a Buy rating. Stifel and Canaccord Genuity (TSX:CF) also maintained their Buy ratings on the company, despite adjustments in their price targets.
Rani Therapeutics has also announced a collaboration with South Korean biotech firm, ProGen Co., Ltd., to co-develop and commercialize RT-114, an oral therapeutic for obesity. Both companies have agreed on a 50/50 cost and revenue share arrangement. Furthermore, the company has appointed Marcum LLP as its new independent registered public accounting firm, replacing Ernst & Young LLP, with no disagreements reported on matters of accounting principles, practices, financial statement disclosure, or auditing procedures leading up to the change.
InvestingPro Insights
The recent stock sales by major shareholders of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) come amid a complex financial landscape for the company. According to InvestingPro data, Rani's market capitalization stands at $139.93 million, reflecting its current position in the biotech sector.
InvestingPro Tips highlight that Rani has experienced a significant return over the last week, with a 12.55% price increase. This short-term gain contrasts sharply with the company's longer-term performance, as the stock has taken a substantial hit over the last six months, declining by 66.88%.
The company's financial health presents some challenges. An InvestingPro Tip notes that Rani is quickly burning through cash, which aligns with the negative EBITDA of $56.9 million for the last twelve months as of Q2 2024. Additionally, the company is not profitable over the last twelve months, with a negative operating income of $57.85 million.
Despite these financial hurdles, analysts have set a fair value target of $11 per share, significantly higher than the previous closing price of $2.60. This disparity suggests potential upside if the company can overcome its current challenges.
For investors seeking a more comprehensive analysis, InvestingPro offers 8 additional tips for Rani Therapeutics, providing deeper insights into the company's financial situation and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.